Table 1.
Formulation details for tacrolimus-loaded conventional liposomes and liposomes containing sodium taurocholate, sodium deoxycholate, or sodium glycoholate for in vitro and in vivo studies (n = 3)
| Liposome formulation | SPC/BS (CH) ratio | TLM loading (%) | Particle size (nm) | Polydispersity | Zeta potential (mV) | Entrapment efficiency (%) |
|---|---|---|---|---|---|---|
| STC-Lip | 5/1 | 5.9 | 97.3 ± 1.6 | 0.267 ± 0.033 | −25.2 ± 3.8 | 95.15 ± 1.91 |
| SDC-Lip | 5/1 | 5.9 | 98.1 ± 5.2 | 0.233 ± 0.013 | −27.8 ± 4.9 | 92.11 ± 1.66 |
| SGC-Lip | 5/1 | 5.9 | 92.8 ± 3.2 | 0.254 ± 0.023 | −21.9 ± 3.1 | 94.97 ± 2.25 |
| CH-Lip | 12/1 | 5.9 | 108.3 ± 2.6 | 0.205 ± 0.017 | −1.2 ± 0.3 | 96.53 ± 3.18 |
Abbreviations: BS, bile salts; CH-Lip, liposomes containing cholesterol; SGC-Lip, liposomes containing sodium glycocholate; SDC-Lip, liposomes containing sodium deoxycholate; STC-Lip, liposomes containing sodium taurocholate; SPC, soybean phosphatidylcholine; TLM, tacrolimus.